![](http://www.acts.co.za/resources/images/filetype_pdf.png)
R 385
Compensation for Occupational Injuries and Diseases Act, 1993 (Act No. 130 of 1993)Scale of FeesAnnual Increase in Medical Tariffs for Medical Service Providers - 2022Doctors Gazette 2022Part lll : Procedures21. Pathology21.1 Haematology |
|
|
Pathologist |
Other Specialists and General Practitioners |
||
U |
R |
U |
R |
||
|
Notes: For fees for Histology and Cytology refer to items 4561 to 4595 under section 22: Anatomical Pathology |
|
|
|
|
|
|
|
|
|
|
|
The amounts in this section are calculated according to the Clinical Pathology unit values |
|
|
|
|
|
|
|
|
|
|
3705 |
Alkali resistant haemoglobin |
4.5 |
132.84 |
3 |
88.56 |
3709 |
Antiglobulin test (Coombs' or trypsinzied red cells) |
3.65 |
107.75 |
2.45 |
72.32 |
3710 |
Antibody titration |
7.2 |
212.54 |
4.8 |
141.70 |
3711 |
Ameth count |
2.25 |
66.42 |
1.5 |
44.28 |
3712 |
Antibody identification |
8.45 |
249.44 |
5.65 |
166.79 |
3713 |
Bleeding time (does not include the cost of the simplate device) |
6.94 |
204.87 |
4.63 |
136.68 |
3715 |
Buffy Layer examination |
19.9 |
587.45 |
13.27 |
391.73 |
3716 |
Mean Cell Volume |
2.25 |
66.42 |
1.5 |
44.28 |
3717 |
Bone marrow cytological examination only |
19.9 |
587.45 |
13.27 |
391.73 |
3719 |
Bone marrow: Aspiration |
8.4 |
247.97 |
5.6 |
165.31 |
3720 |
Bone marrow trephine biopsy |
32.6 |
962.35 |
21.7 |
640.58 |
3721 |
Bone marrow aspiration and trephine biopsy (excluding histological examination) |
36.8 |
1 086.34 |
24.5 |
723.24 |
3722 |
Capillary fragility: Hess |
2.02 |
59.63 |
1.35 |
39.85 |
3723 |
Circulating anticoagulants |
5.85 |
172.69 |
3.9 |
115.13 |
3724 |
Coagulation factor inhibitor assay |
57.56 |
1 699.17 |
38.37 |
1 132.68 |
3726 |
Activated protein C resistance |
26 |
767.52 |
17.3 |
510.70 |
3727 |
Coagulation time |
3.16 |
93.28 |
2.11 |
62.29 |
3728 |
Anti -factor Xa Activity |
53.6 |
1 582.27 |
35.73 |
1 054.75 |
3729 |
Cold agglutinins |
3.6 |
106.27 |
2.4 |
70.85 |
3730 |
Protein S: Functional |
37.5 |
1 107.00 |
25 |
738.00 |
3731 |
Compatability for blood transfusion |
3.6 |
106.27 |
2.4 |
70.85 |
3734 |
Protein C (chromogenic) |
30.29 |
894.16 |
20.19 |
596.01 |
3739 |
Erythrocyte count |
2.25 |
66.42 |
1.5 |
44.28 |
3740 |
Factors V and VII: Qualitative |
7.2 |
212.54 |
4.8 |
141.70 |
3741 |
Coagulation factor assay: functional |
9.45 |
278.96 |
6.3 |
185.98 |
3742 |
Coagulation factor assay: Immunological |
4.5 |
132.84 |
3 |
88.56 |
3743 |
Erythrocyte sedimentation rate |
2.5 |
73.80 |
1.67 |
49.30 |
3744 |
Fibrin stabilising factor (urea test) |
4.5 |
132.84 |
3 |
88.56 |
3746 |
Fibrin monomers |
2.7 |
79.70 |
1.8 |
53.14 |
3748 |
Plasminogen Activator Inhibitor (PAI-I) |
65.95 |
1 946.84 |
43.97 |
1 297.99 |
3750 |
Tissue Plasminogen Activator (tPA |
67.79 |
2 001.16 |
45.19 |
1 334.01 |
3751 |
Osmotic fragility (screen) |
2.25 |
66.42 |
1.5 |
44.28 |
3753 |
Osmotic fragility (before and after incubation) |
18 |
531.36 |
12 |
354.24 |
3754 |
ABO Reverse Groups |
5.5 |
162.36 |
3.67 |
108.34 |
3755 |
Full blood count (including items 3739, 3762, 3783, 3785, 3791) |
10.5 |
309.96 |
7 |
206.64 |
3756 |
Full cross match |
7.2 |
212.54 |
4.8 |
141.70 |
3757 |
Coagulation factors (quantitative) |
32.2 |
950.54 |
21.47 |
633.79 |
3758 |
Factor VIII related antigen |
60.46 |
1 784.78 |
40.31 |
1 189.95 |
3759 |
Coagulation factor correction study |
11.72 |
345.97 |
7.81 |
230.55 |
3761 |
Factor XIII related antigen |
61.11 |
1 803.97 |
40.74 |
1 202.64 |
3762 |
Haemoglobin estimation |
1.8 |
53.14 |
1.2 |
35.42 |
3763 |
Contact activated product essay |
16.2 |
478.22 |
10.8 |
318.82 |
3764 |
Grouping: A-, B- and O- antigens |
3.6 |
106.27 |
2.4 |
70.85 |
3765 |
Grouping; Rh antigens |
3.6 |
106.27 |
2.4 |
70.85 |
3766 |
PIVKA |
43.49 |
1 283.82 |
28.99 |
855.78 |
3767 |
Euglobulin lysis times |
25.58 |
755.12 |
17.05 |
503.32 |
3768 |
Haemoglobin A2 (column chromatography) |
15 |
442.80 |
10 |
295.20 |
3769 |
HB Electrophoresis |
26.82 |
791.73 |
17.88 |
527.82 |
3770 |
Haemoglobin-S (solubility test) |
3.6 |
106.27 |
2.4 |
70.85 |
3773 |
Ham's acidified serum test |
8 |
236.16 |
5.33 |
157.34 |
3775 |
Heinz bodies |
8 |
236.16 |
5.33 |
157.34 |
3776 |
Haemosiderin in urinary sediment |
2.25 |
66.42 |
1.5 |
44.28 |
3777 |
DELETED 2009: Heparin estimation |
|
|
|
|
3781 |
Heparin tolerence |
7.2 |
212.54 |
4.8 |
141.70 |
3783 |
Leucocyte differential count |
6.2 |
183.02 |
4.15 |
122,51 |
3785 |
Leucocytes: total count |
1.8 |
53.14 |
1.2 |
35.42 |
3786 |
QBC malaria concentration and fluorescent staining |
25 |
738.00 |
16.7 |
492.98 |
3787 |
LE-cells |
8.3 |
245.02 |
5.55 |
163.84 |
3789 |
Neutrophil alkaline phosphatase |
28 |
826.56 |
18.7 |
552.02 |
3791 |
Packed cell volume: Haematocrit |
1.8 |
53.14 |
1.2 |
35.42 |
3792 |
Plasmodium falciparum: Monoclonal immunological identification |
9 |
265.68 |
6 |
177.12 |
3793 |
Plasma haemoglobin |
6.75 |
199.26 |
4.5 |
132.84 |
3794 |
Platelet Sensitivities |
18.64 |
550.25 |
12.43 |
366.93 |
3795 |
Platelet aggregation per aggregant |
12.14 |
358.37 |
8.09 |
238.82 |
3796 |
Platelet antibodies: agglutination |
5.4 |
159.41 |
3.6 |
106.27 |
3797 |
Platelet count |
2.25 |
66.42 |
1.5 |
44.28 |
3799 |
Platelet adhesiveness |
4.5 |
132.84 |
3 |
88.56 |
3801 |
Prothrombin consumption |
5.85 |
172.69 |
3.9 |
115.13 |
3803 |
Prothrombin determination (two stages) |
5.85 |
172.69 |
3.9 |
115.13 |
3805 |
Prothrombin index |
6 |
177.12 |
4 |
118.08 |
3806 |
Therapeutic drug level: Dosage |
4.5 |
132.84 |
3 |
88.56 |
3907 |
Recalcification time |
2.25 |
66.42 |
1.5 |
44.28 |
3809 |
Reticulocyte count |
3 |
88.56 |
2 |
59.04 |
3811 |
Sickling test |
2.25 |
66.42 |
1.5 |
44.28 |
3814 |
Sucrose lysis test for PNH |
3.6 |
106.27 |
2.4 |
70.85 |
3816 |
T and B-cells EAC markers (limited to ONE marker only fof CD4/8 counts) |
21.1 |
622.87 |
14.07 |
415.35 |
3820 |
Thrombo-Elastogram |
26 |
767.52 |
17.33 |
511.58 |
3825 |
Fibrinogen titre |
3.6 |
106.27 |
2.4 |
70.85 |
3829 |
Glucose 6-phosphate-dehydragenase: Qualitative |
8 |
236.16 |
5.33 |
157.34 |
3830 |
Glucose 6-phosphate-dehydrogenase: quantitative |
16 |
472.32 |
10.7 |
315.86 |
3832 |
Red cell pyruvate kinase: quantitative |
16 |
472.32 |
10.7 |
315.86 |
3834 |
Red cell Rhesus phenotype |
9.9 |
292.25 |
6.6 |
194.83 |
3835 |
Haemoglobin F in blood smear |
5.85 |
172.69 |
3.9 |
115.13 |
3837 |
Partial thromboplastin time |
5.85 |
172.69 |
3.9 |
115.13 |
3841 |
Thrombin time (screen) |
5.85 |
172.69 |
3.9 |
115.13 |
3843 |
Thrombin time (serial) |
7.65 |
225.83 |
5.1 |
150.55 |
3847 |
Haemoglobin H |
2.25 |
66.42 |
1.5 |
44.28 |
3851 |
Fibrin degeneration products (diffusion plate) |
10.35 |
305.53 |
6.9 |
203.69 |
3853 |
Fibrin degeneration products (latex slide) |
4.5 |
132.84 |
3 |
88.56 |
3854 |
XDP (Dimer test or equivalent latex slide test) |
8.5 |
250.92 |
5.67 |
167.38 |
3856 |
D-Dimer |
27.52 |
812.39 |
18.35 |
541.69 |
3855 |
Hemagglutination inhibition |
9.9 |
292.25 |
6.6 |
194.83 |
3858 |
Heparin Removal |
28.88 |
852.54 |
19.25 |
568.26 |